A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
A phase 2 trial of HLX10+chemo in small-cell lung cancer, run by Shanghai Henlius Biotech, active and no longer recruiting.
Overview
A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC is a phase 2 interventional study registered as NCT06812260 by Shanghai Henlius Biotech, with 26 participants enrolled, started 2025-06-24 and due to reach its primary completion in 2026-10-22. Interventions recorded: HLX10+chemo.
Similar pages
not linked directly; found by shared links- TrialA Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Shares Shanghai Henlius Biotech and the tag pipeline.
- TrialPhase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
Shares Shanghai Henlius Biotech and the tag pipeline.
- TrialA Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
Shares Shanghai Henlius Biotech and the tag pipeline.
- TrialA Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
Shares Shanghai Henlius Biotech and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Shares Small-cell lung cancer and the tag pipeline.
- TrialSNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
Shares Small-cell lung cancer and the tag pipeline.
- TrialAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Shares Small-cell lung cancer and the tag pipeline.
- TrialAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Shares Small-cell lung cancer and the tag pipeline.